Eyenovia, Inc. to Post Q3 2023 Earnings of ($0.16) Per Share, Brookline Capital Management Forecasts (NASDAQ:EYEN)

Posted by Defense World Staff on Oct 20th, 2023

Eyenovia, Inc. (NASDAQ:EYEN – Free Report) – Equities researchers at Brookline Capital Management issued their Q3 2023 earnings per share estimates for shares of Eyenovia in a research report issued to clients and investors on Monday, October 16th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings of ($0.16) per share for the quarter. Brookline Capital Management has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.69) per share. Brookline Capital Management also issued estimates for Eyenovia’s Q4 2023 earnings at ($0.17) EPS, FY2023 earnings at ($0.65) EPS, Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.20) EPS, Q4 2024 earnings at ($0.19) EPS and FY2024 earnings at ($0.83) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Eyenovia in a research report on Friday, August 18th.

Get Our Latest Stock Report on EYEN

Eyenovia Stock Performance

Shares of EYEN opened at $1.33 on Thursday. The firm has a market capitalization of $50.82 million, a PE ratio of -1.93 and a beta of 1.68. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.73 and a quick ratio of 5.73. The company has a 50-day simple moving average of $1.72 and a two-hundred day simple moving average of $2.66. Eyenovia has a one year low of $1.31 and a one year high of $5.85.

Eyenovia (NASDAQ:EYEN – Get Free Report) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04.

Insider Buying and Selling

In other Eyenovia news, major shareholder Stuart M. Grant acquired 45,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were purchased at an average cost of $1.91 per share, for a total transaction of $85,950.00. Following the completion of the purchase, the insider now owns 5,239,998 shares in the company, valued at $10,008,396.18. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have bought 52,357 shares of company stock valued at $98,361 in the last ninety days. 7.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. State Street Corp increased its stake in shares of Eyenovia by 9.3% during the first quarter. State Street Corp now owns 61,617 shares of the company’s stock worth $188,000 after purchasing an additional 5,217 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Eyenovia by 22.8% in the 2nd quarter. Renaissance Technologies LLC now owns 156,000 shares of the company’s stock valued at $304,000 after purchasing an additional 29,000 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Eyenovia by 27.0% in the 2nd quarter. Millennium Management LLC now owns 112,654 shares of the company’s stock valued at $220,000 after buying an additional 23,950 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Eyenovia during the 2nd quarter worth $33,000. Finally, Geode Capital Management LLC lifted its stake in shares of Eyenovia by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 260,067 shares of the company’s stock worth $423,000 after acquiring an additional 6,056 shares during the period. Hedge funds and other institutional investors own 16.66% of the company’s stock.

Eyenovia Company Profile

(Get Free Report)

Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.